FDA Approves Alzheimer’s Drug: Aduhelm


Confidio, Teams, Jody Hessen, RPh
Jody Hessen, RPh
Clinical Consultant

Confidio, Teams, Brian Maas, RPh
Brian Maas, RPh
Clinical Consultant

On June 7, 2021, the FDA approved Aduhelm for the treatment of Alzheimer’s disease. Aduhelm is the first medication approved to treat Alzheimer’s in nearly 20 years. The approval of Aduhelm has garnered significant interest and excitement for the Alzheimer’s community due to the number of patients living with this devastating disease.

The Alzheimer’s Association recently reported that more than 6 million Americans live with Alzheimer’s disease, with a projected 3-fold increase by 2050. In addition, over 11 million Americans provide unpaid care for people with Alzheimer’s or other dementias.

Medications previously approved for the treatment of Alzheimer’s only target the associated symptoms. Aduhelm offers the first approved treatment to address the disease process. While the approval of Aduhelm may provide a new treatment option, the FDA’s independent advisory committee and other experts have questioned the clinical benefit of this medication.

Aduhelm’s initial two clinical trials reported conflicting results related to the clinical benefit. The FDA recognizes that clinical trials of the drug have provided incomplete evidence to demonstrate effectiveness. Still, they proceeded with the approval for the drug to be used with an additional requirement that Biogen conduct a new clinical trial. The FDA reserves the right but is not required to rescind approval if the new trial fails to demonstrate efficacy.

In addition to the FDA Advisory Committee unanimously recommending that it NOT be approved, the Institute for Clinical and Economic Review (ICER, a well-respected authority on cost-effectiveness of drugs) stated that in approving Aduhelm, the FDA has “has failed in its responsibility to protect patients and families from unproven treatments with known harms.” However, the FDA defends its position, citing the reduction in the underlying cause of Alzheimer’s and the fact that the disease is prevalent and devastating with no current disease-modifying treatments available.

Biogen, the manufacturer of Aduhelm, stated the list price would be $56,000 annually, exceeding ICER’s cost-effectiveness threshold of $2,500-$8,300. In addition, there will most likely be significant costs for diagnostic testing and brain imaging. Because Alzheimer’s primarily affects the elderly, most costs are expected to fall under Medicare’s Part B program; CMS has not indicated how it would cover the drug and its associated costs.

Given FDA’s unlimited approval, the widespread nature of this disease also introduces the potential to overwhelm critical resources such as infusion sites, diagnostic imaging centers, and specialist care.

Confidio is working closely with our PBM partners to understand their plans for coverage of this product. As your most trusted consulting partner, Confidio will communicate with clients as information is available.


1. Belluck, P. and Robbins, R. F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works. NY Times. June 7, 2021

2. Alzheimer’s Association. (2020, March 10). 2020 Alzheimer’s disease facts and figures. Retrieved from alz-journals:

3. Institute for Clinical and Economic Review. ICER Issues Statement on the FDA’s Approval of Aducanumab for Alzheimer’s Disease. Boston: June 7, 2021. accessed 6/8/2021.

4. Cavazzoni, P. (2021). FDA’s Decision to Approve New Treatment for Alzheimer’s Disease. Beltsville MD: FDA Center for Drug Evaluation and Research.

5. Joseph A. An extra twist in the FDA Alzheimer’s decision: no limits on which patients can get the drug. STAT News, 6/7/2021., accessed 6/7/2021.



Articles & Announcements

COVID Vaccine Update: Understanding Immunity and Potential for Boosters
FDA Approves Alzheimer’s Drug: Aduhelm
Confidio Expands Investment in Innovation and Continues to Grow Team
Important Changes in Healthcare Promoting Drug Price Transparency
COVID Vaccine Update
Breaking Down Barriers to Cancer Treatment: Problems and Solutions
Is your specialty drug management program only addressing half of your specialty spend?
The High Cost of Hemophilia A Treatments
Navigating HIV PrEP and the Affordable Care Act
Amazon launches “Amazon Pharmacy”, an online pharmacy store
The COVID Vaccine Derby: A Guide to the Top Contenders
Updated executive order on drug pricing, signed by President Trump
Confidio Hires 18 New Employees, Including 3 Strategic Executives
Are Brand-Name Drugs Safer Than Generics?
Understanding COVID-19’s Impact on pharmacy, the Economy and Our Future
President Trump’s Executive Orders on Drug Pricing
CONFIDIO Ranks No. 452 on the 2020 Inc. 5000 With Three-Year Revenue Growth of 1014.66%
Health Alert Updates: COVID-19
Emerging Treatments for Peanut Allergies
HHS Deploys Strategy to Import Drugs From Canada
White House reversal on Proposal to Eliminate Drug Rebates and Pushing Discounts to Point-of-Sale
BBJ’s Employee Benefits Administrators Listing
Will the Rebate Bubble Burst?
Valsartan Drug Recall Notice
Pharmacy Benefits 2020: Ready to Spend Half of Your Medical Plan Budget on Rx?
Pharmacy Predictions: 2019